Discovery and preclinical investigation of the first Type II inhibitor of the SRC kinase.
Ponente
Asier Unciti-Broceta
FRSC. Personal Chair of Medicinal Chemistry and Head of the Innovative Therapeutics Lab. Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, The University of Edinburgh.
